Question explored with the scientific record
Conversation so far
- 1 any general benefits from taking benfotiamine
- 2 any general benefits from taking benfotiamine for a person with charcot-marie-tooth neuropathy
Answered on this page ↓
any general benefits from taking benfotiamine for a person with charcot-marie-tooth neuropathy
The honest answer: no study here tested benfotiamine in Charcot-Marie-Tooth, and the case for it rests on a different disease.
CMT is genetic. CMT1A comes from a duplicated PMP22 gene, and severity is not set by copy number alone [4] and the core problem is altered Schwann cell-to-nerve signaling [5]. Benfotiamine is a fat-soluble form of vitamin B1 [2]. None of the records connect the two. Every human benfotiamine trial here is in diabetic neuropathy, where it eased pain and vibration sense over six weeks [1] and improved symptoms in short trials, while long-term benefit stayed unclear [2][3].
| Question | What the records show |
|---|---|
| Tested in CMT? | No record |
| Diabetic nerve pain | Symptoms improved, 6 weeks [1] |
| Long-term nerve protection | Unproven [2][3] |
| CMT cause | Genetic, PMP22 dosage [4][5] |
So the paper case is a plausible guess filled in from one nerve disease, and the CMT-to-CMT chain was never built. There is one safety note worth stating plainly: benfotiamine is a B vitamin, so it is a low-risk thing to try, not a benign nothing. B vitamins are not free of effect at high dose, and no record here gives long-term dosing data in known neuropathy.
My call: skip it unless you are in a trial, because the evidence is for a different disease and never touched CMT. Confidence: moderate, with the CMT specific evidence essentially absent.
Sources used 5
-
Effectiveness of Different Benfotiamine Dosage Regimens in the Treatment of Painful Diabetic Neuropathy
This study evaluates the effectiveness of different benfotiamine dosage regimens in treating painful diabetic neuropathy, comparing high and medium doses of a benfotiamine-vitamin B combination to a monotherapy with benfotiamine over a 6-week period.
DOI: 10.1055/s-0031-1300405 -
Current concepts in the management of diabetic polyneuropathy
This article reviews the epidemiology, diagnostic criteria, and multimodal management of diabetic sensorimotor polyneuropathy (DSPN), highlighting its high prevalence and underdiagnosis, the limited long-term efficacy of pathogenetically targeted therapies, and the need for harm…
DOI: 10.1111/jdi.13401 -
Diabetic neuropathy
This Nature Reviews Neurology Primer provides a comprehensive synthesis of diabetic neuropathy, detailing its epidemiology, pathophysiology, diagnostic approaches, prevention, and current and emerging treatments, with emphasis on metabolic, vascular, and insulin-signaling disrup…
DOI: 10.1038/s41572-019-0092-1 -
Patients homozygous for the 17p 11.2 duplication in charcot‐marie‐tooth type 1A Disease
Severity of Charcot-Marie-Tooth type 1A associated with the 17p11.2 duplication is not determined solely by PMP22 copy number; homozygotes show variable phenotypes and are not consistently more severely affected than heterozygotes.
DOI: 10.1002/ana.410410117 -
Understanding Schwann cell–neurone interactions: the key to Charcot–Marie–Tooth disease?*
Altered Schwann cell-neurone interactions, particularly due to PMP22 gene dosage or mutations, underlie Charcot-Marie-Tooth disease type 1A and related neuropathies.
DOI: 10.1046/j.1469-7580.2002.00044.x